Email updates

Keep up to date with the latest news and content from Alzheimer's Research & Therapy and BioMed Central.

Review

Technical aspects of amyloid imaging for Alzheimer's disease

Paul Edison1*, Rainer Hinz2 and David J Brooks1

Author Affiliations

1 Medical Research Council Clinical Sciences Centre and Division of Neuroscience, Imperial College London, Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

2 Wolfson Molecular Imaging Centre, University of Manchester, 27 Palatine Road, Withington, Manchester M20 3LJ, UK

For all author emails, please log on.

Alzheimer's Research & Therapy 2011, 3:25  doi:10.1186/alzrt87

Published: 31 August 2011

Abstract

[11C]Pittsburgh Compound B positron emission tomography has now been extensively used to evaluate the amyloid load in different types of dementia and has become a powerful research tool in the field of neurodegenerative diseases. In the present short review we discuss the properties of amyloid imaging agent [11C]Pittsburgh Compound B, the different modalities of molecular imaging, image processing and data analysis, and newer amyloid imaging agents.